As per its latest Enforcement Report, the US health regulator noted that a US-based unit of Glenmark Pharmaceuticals is recalling 26,928 packs of oral contraceptive medication in the US.
Mahwah, New Jersey-based Glenmark Pharmaceuticals Inc, USA is recalling the affected lot of Viorele, Desogestrel and Ethinyl Estradiol (USP, 0.15 mg/ 0.02 mg) and Ethinyl Estradiol tablets due to “failed impurities/degradation specifications.” The affected lot was produced at Mumbai-headquartered drug maker’s Goa manufacturing facility.
The drug firm issued the Class II nationwide recall on September 3, 2025.
USFDA stated that a US-based subsidiary of Dr Reddy’s Laboratories is recalling the medication used to provide muscle relaxation during surgery.
Princeton, New Jersey-based Dr. Reddy’s Laboratories, Inc is recalling 571 vials of Succinylcholine Chloride Injection due to “out-of-specification results during the 6-month stability testing”, USFDA stated. The company initiated the Class II recall on September 26 this year. As per the USFDA, a Class-II recall is initiated when the use of, or exposure to, a violative product may lead to temporary or medically reversible health consequences, or when the likelihood of serious adverse health outcomes is minimal.
India has the highest number of USFDA-compliant pharmaceutical plants outside of the US.
